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Although axonal extension to reconstruct spinal tracts should be effective for restoring
function after spinal cord injury (SCI), chondroitin sulfate proteoglycan (CSPG) levels
increase at spinal cord lesion sites, and inhibit axonal regrowth. In this study, we found
that the water extract of roots of Sophora flavescens extended the axons of mouse
cortical neurons, even on a CSPG-coated surface. Consecutive oral administrations of S.
flavescens extract to SCI mice for 31 days increased the density of 5-HT-positive axons at
the lesion site and improved the motor function. Further, the active constituents in the S.
flavescens extract were identified. The water and alkaloid fractions of the S. flavescens
extract each exhibited axonal extension activity in vitro. LC/MS analysis revealed that
these fractions mainly contain matrine and/or oxymatrine, which are well-known major
compounds in S. flavescens. Matrine and oxymatrine promoted axonal extension on
the CSPG-coated surface. This study is the first to demonstrate that S. flavescens
extract, matrine, and oxymatrine enhance axonal growth in vitro, even on a CSPG-coated
surface, and that S. flavescens extract improves motor function and increases axonal
density in SCI mice.
Keywords: Sophora flavescens, matrine, oxymatrine, axonal growth, chondroitin sulfate proteoglycan, spinal cord
injury
INTRODUCTION
People who have suffered spinal cord injury (SCI) have serious motor dysfunction and abnormal
sensation due to the disruption of the descending motor and ascending sensory tracts at the
lesion site. Although no effective drug therapy currently exists, the reconstruction of spinal
tracts by axonal growth is the most effective strategy for regaining function. At the lesion site,
reactive astrocytes produce inhibitory extracellular matrix molecules, such as chondroitin sulfate
proteoglycan (CSPG; McKeon et al., 1999; Tang et al., 2003). Because the degradation of CSPG
by chondroitinase ABC (ChABC) led to functional recovery in SCI rats (Bradbury et al., 2002),
CSPG has received attention as amajormolecule that inhibits axonal growth. This approach utilizes
intrinsic axonal growth activity. In contrast, we aimed to look for strong axonal growth activity that
is not defeated by CSPG. To find this activity, we previously performed a CSPG coating assay and
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screened water extracts of 110 types of crude drugs that have
been used in traditional Japanese medicine. In this assay, the
extract of dried roots of Sophora flavescens Aiton (Leguminosae)
exhibited remarkable capability to stimulate axonal growth on a
CSPG coating.
The dried roots of S. flavescens, Sophorae Radix, is an anti-
febrile, diuretic, and anti-parasitic agent (Commission of Chinese
Pharmacopoeia, 2010) and has been used traditionally in many
countries, including China, Korea, and Japan. In this study,
new therapeutic potential of dried roots of S. flavescens was
investigated in SCI mice.
MATERIALS AND METHODS
All experiments were performed in accordance with the
Guidelines for the Care and Use of Laboratory Animals of
the University of Toyama. The committee for Animal Care
and Use at the Sugitani Campus of the University of Toyama
approved the study protocols. The approval number for the
animal experiments is A2013INM-1. All efforts were made to
minimize the number of animals used.
FIGURE 1 | S. flavescens extract promotes axonal extension on the CSPG coating. Cortical neurons were cultured for 1 day and then treated with S.
flavescens extract (1 and 10µg/ml) or vehicle solution. Four days after treatment, the cells were fixed and immunostained for pNF-H and MAP2. (A) Representative
immunofluorescence images of pNF-H for each treatment. (B) The densities of pNF-H-positive axons per neuron were quantified for each treatment. The numbers in
parentheses indicate the measured number of captured images. *p < 0.05 vs. CSPG coating/vehicle-treated group, One-way ANOVA post hoc Bonferroni test. Scale
bar = 200µm.
Preparation of Extracts and Fractions
Dried roots of S. flavescens, which were collected from Hebei
Province, Guizhou Province and Shanxi Province, China, were
purchased from Tochimoto Tenkaido (Osaka, Japan; a voucher
specimen NMS No. 002612001). Dried roots of S. flavescens
(280 g) were heated with water in a 20:1 water:root ratio (5.6 L
water) at 100◦C for 1 h. After filtration with a pledget, the extract
was freeze-dried to obtain a powdered extract (43 g; yield was
15.4%).
To obtain subfractions, S. flavescens roots (45 g) were extracted
under the same condition mentioned above. After filtration, a
portion of the extract (300ml) was partitioned twice with ethyl
acetate (100ml). The water layer was mixed with ammonia and
partitioned twice with chloroform (100ml) to obtain an alkaloid
fraction. These extracts were ultimately obtained as powders
(57mg for EtOAc fr., 425mg for alkaloid fr., and 2411mg for
H2O fr.).
Primary Culture and CSPG Coating Assay
Eight-well chamber slides (Falcon, Franklin Lakes, NJ, USA)
were coated with 5µg/ml poly-D-lysine (PDL; Sigma-Aldrich,
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St. Louis, MO, USA) overnight at 37◦C. For the CSPG
coating assay, 2.0µg/ml aggrecan (Sigma-Aldrich), a CSPG,
or vehicle solution was further applied to the PDL-coated
slide for 5 h at 37◦C. Primary cultured cortical cells were
obtained from E14 embryos of ddY mice (Japan SLC, Shizuoka,
Japan) as previously described (Watari et al., 2014). The cells
were cultured on eight-well chamber slides with Neurobasal
medium (Life Technologies, Carlsbad, CA, USA) containing
12% horse serum, 0.6% D-glucose, and 2mM L-glutamine
and maintained at 37◦C in a humidified incubator at 10%
CO2. Five hours after the culture started, the medium was
replaced with fresh Neurobasal medium containing 2% B-27
supplement without horse serum. On the next day of the
culture, the S. flavescens extract (1 and 10µg/ml), ethyl acetate
fraction (1 and 10µg/ml), alkaloid fraction (1 and 10µg/ml),
water fraction (1 and 10µg/ml), matrine (1 and 10µM; Tokyo
Chemical Industry Co., Tokyo, Japan), oxymatrine (1 and
10µM; Santa Cruz Biotechnology Inc., Dallas, TX, USA), or
FIGURE 2 | S. flavescens extract improves motor dysfunction in SCI mice. SCI mice were administered S. flavescens extract (black squares, nine mice, 18
hindlimbs, n = 18) or vehicle solution (white squares, eight mice, 16 hindlimbs, n = 16) once a day from 1h after the injury for 31 days. The motor function of hindlimbs
was assessed using BMS (A), BSS (B), and TMS (C). At 31 days after SCI, the ambulation of a representative SCI mouse treated with vehicle solution (D) or S.
flavescens extract (E) was captured. Sequentially captured images obtained every 0.05 s are shown. *p < 0.0001, time × drug interaction analyzed by repeated
measures Two-way ANOVA. #p < 0.05, post hoc Bonferroni test.
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vehicle solution was applied to the cells. Four days after the
treatment, the cells were fixed with 4% paraformaldehyde and
immunostained with mouse anti-phosphorylated neurofilament-
H (pNF-H, a marker of axons) monoclonal antibody (clone,
SMI-35; dilution, 1:500; Covance, Princeton, NJ, USA) and
rabbit anti-microtubule associated protein 2 (MAP2, a marker
of neuronal cell bodies) polyclonal antibody (dilution, 1:2000;
Abcam, Cambridge, UK). The secondary antibodies were
Alexa Fluor 488-conjugated goat anti-rabbit IgG (dilution,
1:400; Life Technologies) and Alexa Fluor 594-conjugated
goat anti-mouse IgG (dilution, 1:400; Life Technologies). The
cells were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI, a marker of nuclei; 0.1µg/ml; Enzo Life Science,
Farmingdale, NY, USA). Fluorescence images were acquired
at a size of 670 × 890 µm using a BX61/DP70 microscope
(Olympus, Tokyo, Japan). On each image, the total length
of the axons was automatically measured using a Neurocyte
image analyzer (Kurabo, Osaka, Japan), and the number of cell
bodies was manually counted to calculate the axonal density per
neuron.
FIGURE 3 | S. flavescens extract increases the axon density at lesion sites in SCI mice. Sagittal sections of spinal cords were obtained from S. flavescens
extract—or vehicle-treated SCI mice at 31 days after the injury. The sections were immunostained for 5-HT, GFAP, and CSPG. (A) Representative
immunofluorescence images of 5-HT. The yellow solid lines indicate outlines of the spinal cords. The yellow dotted line surrounds the lesion sites identified using the
immunofluorescence images of GFAP. (B–D) The 5-HT-positive area at the lesion site (B), size of the lesion site (C), and expression of CSPG at the lesion site (D) were
quantified. The numbers in parentheses indicate the numbers of mice. *p < 0.05 vs. vehicle group, unpaired two-tailed t-test. Scale bar = 500µm.
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SCI Operation
All mice were housed with ad libitum access to food and
water and were kept in a constant environment (22 ± 2◦C,
50 ± 5% humidity, 12-h light cycle starting at 07:00).
Eight-week-old female ddY mice (SLC) were used for SCI
experiments. The mice were laminectomized under anesthesia
with trichloroacetaldehyde monohydrate (450–500mg/kg, i.p.).
A 6.5-g weight was dropped from a height of 2 cm onto the
exposed spinal cord at T9-10 level using a stereotaxic instrument
(Narishige, Tokyo, Japan) to produce a contusion injury. S.
flavescens extract (500mg/kg/day) or a vehicle control was
continually administered to SCI mice from 1 h after the injury
for 31 days once a day. The hindlimb motor functions of SCI
mice were evaluated using the Basso Mouse Scale (BMS; Basso
et al., 2006), Body Support Scale (BSS; Teshigawara et al., 2013),
and Toyama Mouse Score (TMS; Shigyo et al., 2014) in an
open field (black color, 50.0 × 42.5 × 15.0 cm) under 500-lux
illumination.
Immunohistochemistry
Thirty-one days after the SCI, the mice were anesthetized
by administration of trichloroacetaldehyde monohydrate and
were transcardially perfused with ice-cold saline and 4%
paraformaldehyde. Spinal cord tissues around the injured region
were removed and soaked in 4% paraformaldehyde and then
solutions of increasing sucrose concentration (10, 20, and
30%). The spinal cord tissues were cut into 12-µm successive
sagittal sections using a CM3050S cryostat (Leica, Heidelberg,
Germany). The slices were fixed with 4% paraformaldehyde and
immunostained with rabbit anti-5-hydroxytryptamine (5-HT, a
marker of the raphespinal tract) polyclonal antibody (dilution
1:500; ImmunoStar, Hudson, Wisconsin, USA), mouse anti- glial
FIGURE 4 | The alkaloid fraction and the water fraction promote axonal extension on the CSPG coating. Cortical neurons were cultured for 1 day and then
treated with the ethyl acetate fraction (1 and 10µg/ml), the alkaloid fraction (1 and 10µg/ml), the water fraction (1 and 10µg/ml), S. flavescens extract (10µg/ml), or
vehicle solution. Four days after treatment, the cells were fixed and immunostained for pNF-H and MAP2. (A) Representative immunofluorescence images of pNF-H
for each treatment. (B) The densities of pNF-H-positive axons per neuron were quantified for each treatment. The numbers in parentheses indicate the measured
number of captured images. *p < 0.05 vs. CSPG coating/vehicle-treated group, One-way ANOVA post hoc Bonferroni test. Scale bar = 200µm.
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fibrillary acidic protein (GFAP, a marker of reactive astrocytes)
monoclonal antibody (clone, G-A-5; dilution 1:1000; Sigma-
Aldrich), and mouse anti-CSPG monoclonal antibody (clone,
CS-56; dilution 1:500; Sigma-Aldrich). The secondary antibodies
were Alexa Fluor 488-conjugated goat anti-rabbit IgG (dilution,
1:200; Life Technologies), Alexa Fluor 594-conjugated goat
anti-mouse IgG1 (dilution, 1:400; Life Technologies), and Alexa
Fluor 350-conjugated goat anti-mouse IgM (dilution, 1:400;
Life Technologies). Fluorescence images were acquired using an
Axio Observer Z1 microscopy system (Carl Zeiss, Oberkochen,
Germany) and tiled. Lesion sites were identified based on the
fluorescence images of GFAP. The sizes of the lesion site,
expression levels of CSPG inside the lesion site and densities of
the 5-HT positive area inside the lesion site were quantified using
ImageJ image analysis software (NIH).
LC/MS Analysis of the Alkaloid Fraction,
the Water Fraction, Matrine, and
Oxymatrine
The alkaloid fraction, the water fraction, matrine, and
oxymatrine were analyzed using a Thermo Scientific LC/MS
system (Thermo Fisher Scientific, Waltham, Massachusetts,
USA), which consisted of an Accella-600 HPLC system with
photodiode array detection and an LTQ Orbitrap XL Mass
Spectrometer. The LC/MS analysis conditions were as follows.
The HPLC conditions: solvent A, 0.1% formic acid in H2O;
solvent B, 0.1% formic acid in MeCN; column, Capcell Pak
C-18 (1.5mm i.d. × 150mm; Shiseido, Tokyo, Japan); flow,
0.20ml/min; gradient program, a linear gradient of 2–35% of
solvent B in solvent A for 15min followed by a linear gradient
of 35–90% of solvent B for 5min, and then maintenance of
90% solvent B in solvent A for 5min; column temp., 25◦C; and
photodiode array detection, 200–600 nm. The MS conditions:
electrospray polarity, positive mode; sheath gas flow, 50 arbitrary
units; aux gas flow, 30 arbitrary units; ion spray voltage, 4.6 kV;
capillary temp., 350◦C; capillary voltage 19.0V; tube lens, 35V;
and detector, an Orbitrap detector with a high resolution of
60,000.
Statistical Analysis
Statistical comparisons were performed through One-way
analysis of variance (ANOVA) with the post hoc Bonferroni test,
repeated measures Two-way ANOVA with post hoc Bonferroni
test, or an unpaired two-tailed t-test using GraphPad Prism 5
(GraphPad Software, San Diego, California, USA). P < 0.05 was
considered significant. The data are presented as the mean± SE.
RESULTS
S. flavescens Extract Promotes Axonal
Extension on a CSPG-Coated Surface
For the CSPG coating assay, culture slides were coated with PDL
and then with CSPG. Axonal density was significantly decreased
on the CSPG substrate compared with that on the PDL substrate
only (Figures 1A,B). S. flavescens extract (10µg/ml) treatment
significantly increased the axonal density on the CSPG substrate
compared with that for the vehicle treatment. The enhancement
of axonal extension by the S. flavescens extract was not observed
under normal coating (Figure 7).
S. flavescens Extract Increases Axons at
the Lesion Site and Improves Motor
Dysfunction in SCI Mice
To investigate the effects of S. flavescens extract in SCI mice,
S. flavescens extract (500mg/kg/day), or vehicle solution was
orally administered to SCI mice. The drug administration was
started from 1 h after the SCI operation and was continued
for 31 days. The hindlimb motor functions were assessed using
BMS, BSS, and TMS for 31 days, once every 2 days. For all of
FIGURE 5 | LC/MS analysis of the alkaloid and water fractions. Photodiode array (PDA) total scan chromatograms, total ion chromatograms, and extracted ion
chromatograms at m/z 249.1967 ± 0.003 and 265.1916 ± 0.003 to detect matrine and oxymatrine, respectively, in the alkaloid fraction and the water fraction. *A
specific peak of matrine; #a specific peak of oxymatrine.
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the evaluation methods, repeated measures Two-way ANOVA
revealed a significant time× drug interaction between the vehicle
group and the S. flavescens extract group [F(15, 480) = 9.434,
p < 0.0001 (BMS; Figure 2A); F(15, 480) = 9.397, p < 0.0001
(BSS; Figure 2B); F(15, 480) = 10.68, p < 0.0001 (TMS;
Figure 2C)]. The scores of S. flavescens extract-treated mice were
significantly higher than those of vehicle-treated mice from 17
to 31 days after the injury for the BMS and TMS evaluations
and from 19 to 31 days after the injury for the BSS evaluation.
At 31 days after the injury, vehicle-treated mice had scores of
2.44 in BMS, 0.75 in BSS, and 8.19 in TMS. These scores show
that the mice could not touch the floor with the soles of their
feet (Figure 2D and Supplementary Video 1). In contrast, S.
flavescens extract-treated mice had scores of 4.00 in BMS, 1.78
in BSS, and 13.6 in TMS, showing that the mice could touch the
floor with the soles of their feet and sometimes could lift up the
hindquarters (Figure 2E, especially the photos at 0.15 and 0.20 s,
and Supplementary Video 2).
To confirm whether axonal extensions at the lesion site were
induced by S. flavescens extract treatment, spinal cords were
isolated at 31 days after the injury. Spinal cord slices were
immunostained for 5-HT (Figure 3A), GFAP, and CSPG. The
molecule 5-HT is amarker of serotonergic raphespinal tracts, one
of the major tracts that regulates motor function (Liu and Jordan,
2005). GFAP is a marker of reactive astrocytes. The lesion site
was defined as the area surrounded by GFAP-positive cells. The
S. flavescens extract showed no effect on the size of the lesion
site (Figure 3C). The density of the 5-HT-positive area at the
lesion site was significantly increased in the S. flavescens extract-
treated mice (Figures 3A,B). However, the S. flavescens extract-
treated group showed significantly upregulated expression levels
of CSPG at the lesion site (Figure 3D). These results suggest that
S. flavescens extract promotes the axonal extension of at least
raphespinal tracts, even in the presence of CSPG in vivo, and the
axonal extension by the S. flavescens extract does not seem to be
blocked by the S. flavescens extract-induced CSPG increase.
Matrine and Oxymatrine are Active
Constituents in S. flavescens Extract for
the Axonal Extension Activity on a
CSPG-Coated Surface
To identify the active constituents in the S. flavescens extract, the
S. flavescens extract was separated into ethyl acetate, alkaloid, and
FIGURE 6 | Matrine and oxymatrine promote axonal extension on the CSPG coating. Cortical neurons were cultured for 1 day and then treated with matrine (1
and 10µM), oxymatrine (1 and 10µM), or vehicle solution. Four days after the treatment, the cells were fixed and immunostained for pNF-H and MAP2. (A)
Representative immunofluorescence images of pNF-H for each treatment. (B) The density of pNF-H-positive axons per neuron were quantified for each treatment.
The numbers in parentheses indicate the measured number of captured images. *p < 0.05 vs. CSPG coating/vehicle-treated group, One-way ANOVA post hoc
Bonferroni test. Scale bar = 200µm.
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water fractions. These fractions (1 and 10µg/ml) were evaluated
for axonal extension activity using the CSPG coating assay
(Figure 4). Compared with vehicle solution, the alkaloid fraction
(1 and 10µg/ml), and the water fraction (10µg/ml) significantly
promoted axonal extension on a CSPG-coated surface, but the
ethyl acetate fraction did not exhibit these effects. This result
suggested that the active constituents in S. flavescens extract
were contained in the alkaloid fraction and the water fraction,
but not in the ethyl acetate fraction. Previous study by Yang
et al. showed that alkaloids were rich in a water layer, and
flavonoids were rich in an ethyl acetate layer when the extract
of S. flavescens was partitioned with water and ethyl acetate
(Yang et al., 2012). We determined whether the alkaloid and
water fractions contained matrine and oxymatrine using LC/MS
analysis (Figure 5) because matrine and oxymatrine are major
alkaloids in S. flavescens (Li and Wang, 2004). Specific peaks of
matrine and oxymatrine were detected at retention times of 2min
and 2min 40 s, respectively. The peak of matrine was detected in
the alkaloid fraction, and the peak of oxymatrine was detected
in both the alkaloid and water fractions. Based on MS analysis,
the molecular weights of these peaks corresponded to matrine
(m/z: 249.1967± 0.003) and oxymatrine (m/z: 265.1916± 0.003).
These results suggested that the alkaloid fraction contained
substantial amount of matrine and oxymatrine and that the water
fraction contained an abundance of oxymatrine. Then, the effects
of matrine (1 and 10µM) and oxymatrine (1 and 10µM) on
axonal extension were evaluated using a CSPG coating assay
(Figure 6). Compared with vehicle solution, matrine (10µM),
and oxymatrine (10µM) significantly increased the axonal
density on the CSPG. When neurons were cultured on a normal
PDL substrate without CSPG, matrine (1 and 10µM), and
oxymatrine (1 and 10µM) induced no axonal growth (Figure 7).
DISCUSSION
Recent studies showed several biological effects of S.
flavescens extract, such as anti-cancer (Xiao et al., 2013),
anti-arrhythmic (Kim et al., 2013), anti-allergic (Dev et al., 2011),
anti-inflammatory (Kim et al., 2012), and anti-asthmatic effects
(Yang et al., 2013). In particular, the anti-cancer effect has been
actively investigated for S. flavescens extract and for several
S. flavescens constituents, including matrine, and oxymatrine
(Ren et al., 2014; Wu et al., 2015). Concerning the effects on
the neuronal function, matrine exhibited protective effects
on neurons and astrocytes under the conditions of oxygen-
and glucose-deprivation, possibly through the inhibition of
nuclear factor-κ B activation (Xu et al., 2012). In a rat model of
experimental autoimmune encephalomyelitis, the administration
of matrine suppressed the reduction of nerve fibers in the brain,
which might relate to the increased level of brain-derived
neurotrophic factor mRNA (Kan et al., 2015). Oxymatrine
provides protective effects to neurons exposed to excessive N-
methyl-D-aspartate (NMDA) via decreases in the up-regulation
of NR2B-containing NMDA receptors, thereby suppressing the
rapid elevation of the intracellular Ca2+ concentration (Zhang
et al., 2013). In this study, we found that S. flavescens extract,
matrine and oxymatrine extended axons, even on a CSPG-coated
surface, and that S. flavescens extract administration ameliorated
the motor dysfunction and increased the axonal density in SCI
mice. These data are all new findings.
Although the CSPG expression at the lesion site in SCI mice
was enhanced by S. flavescens extract administration (Figure 3D),
the mechanism of the S. flavescens treatment-induced CSPG
increase, and the constituents related to the phenomenon are
unclear. Despite the CSPG elevation, axonal extension, and
recovery of motor function were observed in the S. flavescens
extract-treated SCI mice, suggesting that the axonal extension
activity of S. flavescens extract may overcome the presence of
CSPG. Although functional recovery in response to S. flavescens
extract treatment in SCI mice may not be explained completely
by the growth of 5-HT-positive raphespinal tracts, extension of
the raphespinal tracts relates well to the improvement in motor
function (Kim et al., 2004; Teshigawara et al., 2013; Bartus et al.,
2014).
FIGURE 7 | Matrine, oxymatrine, and S. flavescens extract have no effects on axonal extension on the PDL coating. Cortical neurons were cultured for 1
day and then treated with matrine (1 and 10µM), oxymatrine (1 and 10µM), S. flavescens extract (1 and 10µg/ml), or vehicle solution. Four days after the treatment,
the cells were fixed and immunostained for pNF-H and MAP2. The density of pNF-H-positive axons per neuron were quantified for each treatment. The numbers in
parentheses indicate the measured number of captured images.
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At least matrine and oxymatrine are a part of active
constituents in the S. flavescens extract in this study. The
mechanisms relating matrine and oxymatrine to axonal growth
remain unknown, although antagonistic activities of those
compounds on epidermal growth factor receptor (EGFR)
were shown in relation to anti-cancer effects (Wang et al.,
2010; Guo et al., 2015). Interestingly, an EGFR inhibitor
promotes the regeneration of axonal fibers by blocking CSPG
signals (Koprivica et al., 2005). Considering those results, the
inhibition of EGFR signaling may be one possible pathway
for the effects of matrine and oxymatrine. We are now
comprehensively investigating the direct protein targets of
matrine and oxymatrine. In addition, the effects of matrine and
oxymatrine on motor dysfunction in SCI mice are also under
investigation.
CONCLUSION
This study is the first to demonstrate that S. flavescens extract,
matrine and oxymatrine enhance axonal growth in vitro,
even on a CSPG-coated surface, and that S. flavescens extract
improves motor function and increases axonal density in SCI
mice. These findings may lead to the development of a new
SCI therapy.
FUNDING
This work was supported by a Grant-in-Aid for challenging
Exploratory Research No. (26670044) from the Ministry of
Education, Culture, Sports, Science, and Technology of Japan
(CT) and a Grant-in-Aid for The Cooperative Research Project
from Institute of NaturalMedicine, University of Toyama in 2014
and 2015 (CT and TK).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2015.00326
REFERENCES
Bartus, K., James, N. D., Didangelos, A., Bosch, K. D., Verhaagen, J., Yáñez-Muñoz,
R. J., et al. (2014). Large-scale chondroitin sulfate proteoglycan digestion
with chondroitinase gene therapy leads to reduced pathology and modulates
macrophage phenotype following spinal cord contusion injury. J. Neurosci. 34,
4822–4836. doi: 10.1523/JNEUROSCI.4369-13.2014
Basso, D. M., Fisher, L. C., Anderson, A. J., Jakeman, L. B., McTigue, D. M., and
Popovich, P. G. (2006). Basso mouse scale for locomotion detects differences in
recovery after spinal cord injury in five commonmouse strains. J. Neurotrauma
23, 635–659. doi: 10.1089/neu.2006.23.635
Bradbury, E. J., Moon, L. D., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N.,
et al. (2002). Chondroitinase ABC promotes functional recovery after spinal
cord injury. Nature 416, 636–640. doi: 10.1038/416636a
Commission of Chinese Pharmacopoeia (2010). Pharmacopoeia of the People’s
Republic of China, Vol. 1. Beijing: China Medical Science Press.
Dev, S., Mizuguchi, H., Das, A. K., Baba, Y., and Fukui, H. (2011). Transcriptional
microarray analysis reveals suppression of histamine signaling by Kujin
alleviates allergic symptoms through down-regulation of FAT10 expression. Int.
Immunopharmacol. 11, 1504–1509. doi: 10.1016/j.intimp.2011.05.004
Guo, B., Zhang, T., Su, J., Wang, K., and Li, X. (2015). Oxymatrine targets
EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress
the proliferation and invasion of gastric cancer cells. Cancer Chemother.
Pharmacol. 75, 353–363. doi: 10.1007/s00280-014-2651-1
Kan, Q. C., Lv, P., Zhang, X. J., Xu, Y. M., Zhang, G. X., and Zhu, L. (2015). Matrine
protects neuro-axon from CNS inflammation-induced injury. Exp. Mol. Pathol.
98, 124–130. doi: 10.1016/j.yexmp.2015.01.001
Kim, C. Y., Kim, H. J., Kim, K. M., and Oak, M. H. (2013). Vasorelaxant prenylated
flavonoids from the roots of Sophora flavescens. Biosci. Biotechnol. Biochem. 77,
395–397. doi: 10.1271/bbb.120739
Kim, H., Lee, M. R., Lee, G. S., An, W. G., and Cho, S. I. (2012). Effect of Sophora
flavescens Aiton extract on degranulation of mast cells and contact dermatitis
induced by dinitrofluorobenzene in mice. J. Ethnopharmacol. 142, 253–258.
doi: 10.1016/j.jep.2012.04.053
Kim, J. E., Liu, B. P., Park, J. H., and Strittmatter, S. M. (2004). Nogo-
66 receptor prevents raphespinal and rubrospinal axon regeneration and
limits functional recovery from spinal cord injury. Neuron 44, 439–451. doi:
10.1016/j.neuron.2004.10.015
Koprivica, V., Cho, K. S., Park, J. B., Yiu, G., Atwal, J., Gore, B., et al. (2005). EGFR
activation mediates inhibition of axon regeneration by myelin and chondroitin
sulfate proteoglycans. Science 310, 106–110. doi: 10.1126/science.1115462
Li, K., and Wang, H. (2004). Simultaneous determination of matrine, sophoridine
and oxymatrine in Sophora flavescens Ait. by high performance liquid
chromatography. Biomed. Chromatogr. 18, 178–182. doi: 10.1002/bmc.308
Liu, J., and Jordan, L. M. (2005). Stimulation of the parapyramidal region
of the neonatal rat brain stem produces locomotor-like activity involving
spinal 5-HT7 and 5-HT2A receptors. J. Neurophysiol. 94, 1392–1404. doi:
10.1152/jn.00136.2005
McKeon, R. J., Jurynec, M. J., and Buck, C. R. (1999). The chondroitin sulfate
proteoglycans neurocan and phosphacan are expressed by reactive astrocytes
in the chronic CNS glial scar. J. Neurosci. 19, 10778–10788.
Ren, H., Zhang, S., Ma, H., Wang, Y., Liu, D., Wang, X., et al. (2014). Matrine
reduces the proliferation and invasion of colorectal cancer cells via reducing the
activity of p38 signaling pathway. Acta. Biochim. Biophys. Sin. 46, 1049–1055.
doi: 10.1093/abbs/gmu101
Shigyo, M., Tanabe, N., Kuboyama, T., Choi, S. H., and Tohda, C. (2014). New
reliable scoring system, Toyama mouse score, to evaluate locomotor function
following spinal cord injury in mice. BMC Res. Notes 7:332. doi: 10.1186/1756-
0500-7-332
Tang, X., Davies, J. E., and Davies, S. J. (2003). Changes in distribution, cell
associations, and protein expression levels of NG2, neurocan, phosphacan,
brevican, versican V2, and tenascin-C during acute to chronic maturation
of spinal cord scar tissue. J. Neurosci. Res. 71, 427–444. doi: 10.1002/jnr.
10523
Teshigawara, K., Kuboyama, T., Shigyo, M., Nagata, A., Sugimoto, K., Matsuya, Y.,
et al. (2013). A novel compound, denosomin, ameliorates spinal cord injury via
axonal growth associated with astrocyte-secreted vimentin. Br. J. Pharmacol.
168, 903–919. doi: 10.1111/j.1476-5381.2012.02211.x
Wang, S., Sun, M., Zhang, Y., Du, H., and He, L. (2010). A new
A431/cell membrane chromatography and online high performance liquid
chromatography/mass spectrometry method for screening epidermal growth
factor receptor antagonists from Radix sophorae flavescentis. J. Chromatogr. A
1217, 5246–5252. doi: 10.1016/j.chroma.2010.06.037
Watari, H., Shimada, Y., and Tohda, C. (2014). New treatment for alzheimer’s
disease, kamikihito, reverses amyloid-β-induced progression of tau
phosphorylation and axonal atrophy. Evid. Based Complement. Altern.
Med. 2014:706487. doi: 10.1155/2014/706487
Wu, C., Huang, W., Guo, Y., Xia, P., Sun, X., Pan, X., et al. (2015). Oxymatrine
inhibits the proliferation of prostate cancer cells in vitro and in vivo.Mol. Med.
Rep. 11, 4129–4134. doi: 10.3892/mmr.2015.3338
Xiao, Z. M., Wang, A. M., Wang, X. Y., and Shen, S. R. (2013). Effects of
ethanol extract of Radix Sophorae Flavescentis on activity of colon cancer
Frontiers in Pharmacology | www.frontiersin.org 9 January 2016 | Volume 6 | Article 326
Tanabe et al. S. flavescens Improves Spinal Cord Injury
HT29 cells. Afr. J. Tradit. Complement. Altern. Med. 10, 352–355. doi:
10.4314/ajtcam.v10i5.22
Xu, M., Yang, L., Hong, L. Z., Zhao, X. Y., and Zhang, H. L. (2012).
Direct protection of neurons and astrocytes by matrine via inhibition
of the NF-κB signaling pathway contributes to neuroprotection against
focal cerebral ischemia. Brain Res. 1454, 48–64. doi: 10.1016/j.brainres.2012.
03.020
Yang, J. M., Ip, S. P., Xian, Y., Zhao, M., Lin, Z. X., Yeung, J. H.,
et al. (2012). Impact of the herbal medicine Sophora flavescens on the
oral pharmacokinetics of indinavir in rats: the involvement of CYP3A
and P-glycoprotein. PLoS ONE 7:e31312. doi: 10.1371/journal.pone.00
31312
Yang, N., Liang, B., Srivastava, K., Zeng, J., Zhan, J., Brown, L., et al. (2013).
The Sophora flavescens flavonoid compound trifolirhizin inhibits acetylcholine
induced airway smooth muscle contraction. Phytochemistry 95, 259–267. doi:
10.1016/j.phytochem.2013.07.023
Zhang, K., Li, Y. J., Yang, Q., Gerile, O., Yang, L., Li, X. B., et al. (2013).
Neuroprotective effects of oxymatrine against excitotoxicity partially through
down-regulation of NR2B-containing NMDA receptors. Phytomedicine 20,
343–350. doi: 10.1016/j.phymed.2012.10.018
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Tanabe, Kuboyama, Kazuma, Konno and Tohda. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 10 January 2016 | Volume 6 | Article 326
